Anti-CD19 [BU12] mAb

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

• Name: Anti-CD19 [BU12] mAb
• Alternate name: CD19 Molecule; B-Lymphocyte Surface Antigen B4; T-Cell Surface Antigen Leu-12; Differentiation Antigen CD19; CD19 Antigen; CVID3; B4
• Research fields: Cancer;Cell signaling and signal transduction;Immunology;Stem cell biology
• Clone: BU12
• Tool sub type: Primary antibody
• Class: Monoclonal
• Conjugation: Unconjugated
• Strain: Balb/c
• Reactivity: Human
• Host: Mouse
• Application: FACS ; IHC ; IP
• Description: CD19 is a member of the immunoglobulin superfamily and has two Ig like domains. It is a single chain glycoprotein, present on the surface of normal and neoplastic B-cells. CD19 is expressed at an early stage by projenitor B-cells in bone marrow and during all stages of B-cell maturation. This antigen is lost upon terminal differentiation to plasma cells. CD19 is important for detecting both normal and neoplastic B-cells. CD19 is present on neoplasms arising from early B-cells (e.g. acute leukaemia of pre-B-cells) and more differentiated B-cell neoplasms (e.g. chronic Lymphocytic leukaemia and non-Hodgkin's lymphoma). Leukaemia phenotype studies have demonstrated that the earliest and broadest B cell restricted antigen is the CD19 antigen. The CD19 cytoplasmic domain binds tyrosine kinases and PI-3 kinase.
• Immunogen: Human EB-4 Burkitt's lymphoma cell line
• Isotype: IgG1

Target Details

• Target: CD19
• Target background: CD19 is a member of the immunoglobulin superfamily and has two Ig like domains. It is a single chain glycoprotein, present on the surface of normal and neoplastic B-cells. CD19 is expressed at an early stage by projenitor B-cells in bone marrow and during all stages of B-cell maturation. This antigen is lost upon terminal differentiation to plasma cells. CD19 is important for detecting both normal and neoplastic B-cells. CD19 is present on neoplasms arising from early B-cells (e.g. acute leukaemia of pre-B-cells) and more differentiated B-cell neoplasms (e.g. chronic Lymphocytic leukaemia and non-Hodgkin's lymphoma). Leukaemia phenotype studies have demonstrated that the earliest and broadest B cell restricted antigen is the CD19 antigen. The CD19 cytoplasmic domain binds tyrosine kinases and PI-3 kinase.

Applications

• Application: FACS ; IHC ; IP

Handling

• Format: Liquid
• Concentration: 0.9-1.1 mg/ml
• Unit size: 100 ug
• Storage buffer: PBS with 0.02% azide
• Storage conditions: -15° C to -25° C
• Shipping conditions: Shipping at 4° C

References

• Bortolotti et al. 2016. Toxins (Basel). 8(6):. PMID: 27338475.
• High in Vitro Anti-Tumor Efficacy of Dimeric Rituximab/Saporin-S6 Immunotoxin.
• Flavell et al. 2006. Br J Haematol. 134(2):157-70. PMID: 16771848.
• The anti-CD20 antibody rituximab augments the immunospecific therapeutic effectiveness of an anti-CD19 immunotoxin directed against human B-cell lymphoma.
• Behr et al. 1995. J Exp Med. 182(5):1191-9. PMID: 7595190.
• Engaging CD19 or target of an antiproliferative antibody 1 on human B lymphocytes induces binding of B cells to the interfollicular stroma of human tonsils via integrin alpha 4/beta 1 and fibronectin.
• Schlossman SF. et al. 1995. Leucocyte Typing V. Oxford University Press
• Callard et al. 1992. J Immunol. 148(10):2983-7. PMID: 1374445.
• CD19 regulation of human B cell responses. B cell proliferation and antibody secretion are inhibited or enhanced by ligation of the CD19 surface glycoprotein depending on the stimulating signal used.